Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Five9 Inc (FIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Five9 Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $227 (market cap $30.39B), while Five9 Inc trades at $33.63 (market cap $2.53B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 12× Five9 Inc's market cap, and Five9 Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FIVN | |
|---|---|---|
Market Cap | $30.39B | $2.53B |
Sector | Health | Technology |
52-Week High | $491.22 | $34.48 |
52-Week Low | $205.48 | $13.61 |
Enterprise Value | $28.35B | $2.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $227.12, up 2.68% in the last 24 hours, but technical indicators signal a bearish trend with resistance near $229. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with a net income of $313.75M, though recent Q2 2026 earnings missed estimates. Multiple law firms are investigating potential securities fraud, adding to negative sentiment.
Outlook is mixed: analyst consensus remains bullish with a $370.07 price target, but risks include ongoing legal probes, earnings volatility, and high valuation multiples. The stock faces near-term pressure from bearish technicals and investor caution despite solid fundamental progress.
FIVN trades at $33.80, up 3.59% today, near its 52-week high of $34.58. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for three consecutive quarters. Revenue growth is accelerating, with 2025 revenue reaching $1.15 billion and net income turning positive at $39.42 million, marking a significant improvement from prior losses. Recent management appointments and AI-driven subscription growth are positive catalysts.
The outlook is positive given earnings momentum and analyst support, but risks include high valuation multiples, ongoing legal scrutiny, and dependence on competitive AI adoption. With 61% of analysts rating it a Buy and a consensus target of $32.67, near-term upside appears limited, but execution on guidance could drive further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
